Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia

Autor: U. Graubner, M L den Boer, H. J. Spaar, D. Harms, K.M. Kazemier, D. Körholz, Rob Pieters, U. Göbel, Gritta Janka-Schaub, Anjo J.P. Veerman, N. Jorch, Gertjan J.L. Kaspers, R.J. Haas, E. R. Van Wering, W.A. Kamps, A. van der Does-van den Berg

Publikováno v: Den Boer, M L, Harms, D O, Pieters, R, Kazemier, K M, Göbel, U, Körholz, D, Graubner, U, Haas, R J, Jorch, N, Spaar, H J, Kaspers, G J L, Kamps, W A, Van Der Does-Van Den Berg, A, Van Wering, E R, Veerman, A J P & Janka-Schaub, G E 2003, ' Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia ', Journal of Clinical Oncology, vol. 21, no. 17, pp. 3262-3268 . https://doi.org/10.1200/JCO.2003.11.031
Journal of Clinical Oncology, 21(17), 3262-3268. American Society of Clinical Oncology
Journal of Clinical Oncology, 21(17), 3262-3268. AMER SOC CLINICAL ONCOLOGY

Purpose : To confirm the prognostic value of a drug resistance profile combining prednisolone, vincristine, and L-asparaginase (PVA) cytotoxicity in an independent group of children with acute lymphoblastic leukemia (ALL) treated with a different pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e461aeca8c650848653a4d18f1b0e002
https://doi.org/10.1200/jco.2003.11.031

Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood - follow up after 9 years

Autor: U. Graubner, R. J. Haas, U. Goebel, P. Gutjahr, G. E. Janka-Schaub, Dieter Harms, H. Juergens, H. J. Spaar, K. Winkler

Publikováno v: European Journal of Pediatrics. 155:640-648

A frequent change of drug combinations may circumvent drug resistance in the treatment of patients with acute lymphoblastic leukaemia (ALL). In study COALL 85/89 201 children with high-risk ALL were randomized to receive over a period of 8 months rot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f970262565eee5c3d71638f17531f488
https://doi.org/10.1007/s004310050459

[Improved treatment results in children with AML: Results of study AML-BFM 93]

Autor: U, Creutzig, F, Berthold, J, Boos, G, Fleischhack, H, Gadner, A, Gnekow, U, Graubner, G, Henze, J, Hermann, P, Imbach, H, Jürgens, H, Kabisch, D, Körholz, C M, Niemeyer, D, Reinhardt, A, Reiter, J, Ritter, H J, Spaar, M, Zimmermann

Publikováno v: Klinische Padiatrie. 213(4)

In the multicenter trial AML-BFM 93 daunorubicin or idarubicin was randomly applied in all patients during induction in combination with cytarabine and etoposide. After induction all patients were stratified to the standard or high risk group. To imp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a56ccaa47867b93f1f526e46c976c668
https://pubmed.ncbi.nlm.nih.gov/11528551

[Effect of dose intensity and therapy-induced leukocytopenia in intensive therapy on the prognosis of acute lymphatic leukemia in childhood. Results in 213 patients of the COALL-85 study]

Autor: O, Gobrecht, U, Göbel, U, Graubner, P, Gutjahr, V, Schöck, H J, Spaar, G E, Janka-Schaub

Publikováno v: Klinische Padiatrie. 204(4)

Dose intensity (DI) plays an important role in the treatment of neoplastic diseases. The individual DI within a protocol may vary considerably and thus may be an important prognostic factor. In 213/305 patients treated in the cooperative study COALL-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e1d0ebc4a3af87c814223c07480dbc85
https://pubmed.ncbi.nlm.nih.gov/1518258

[Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group]

Autor: G E, Janka-Schaub, H, Stührk, B, Kortüm, U, Graubner, H, Jürgens, H J, Spaar, V, Schöck, B, Dohrn, R, Bahr, K, Winkler

Publikováno v: Klinische Padiatrie. 203(4)

Prognostic factors to estimate the risk of relapse are crucial for risk-adapted therapy in acute lymphoblastic leukemia (ALL). In a cooperative multicenter treatment study for childhood ALL (COALL-03-85) the prognostic relevance of the bone marrow (B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c0b745c3a518631d65cf93b65a489412
https://pubmed.ncbi.nlm.nih.gov/1942930